Results 211 to 220 of about 2,092,286 (303)

A Novel Plasma Biomarker hsa_circ_0080018 Drives DLBCL Progression via M2 Polarization of Tumor‐Associated Macrophages

open access: yesCancer Science, EarlyView.
The proposed mechanistic model in this study. ABSTRACT Noncoding RNAs, including circular RNAs (circRNAs), have been demonstrated to play vital roles in tumorigenesis. Uncovering the functions of circRNAs in tumorigenesis and their underlying regulatory mechanisms may suggest new approaches to the development of novel diagnostic and therapeutic ...
Yanfeng Liu, Yanan Gao, Chuanli Zhao
wiley   +1 more source

The Proteomics of T-Cell and Early T-Cell Precursor (ETP) Acute Lymphocytic Leukemia: Prognostic Patterns in Adult and Pediatric-ETP ALL. [PDF]

open access: yesCancers (Basel)
Hoff FW   +11 more
europepmc   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

open access: yesCancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source

Long-Term Outcomes of Childhood Acute Lymphocytic Leukemia Treated with Adapted Berlin-Frankfurt-Münster (BFM) Protocols: A Multicentric Analysis from a Developing Country. [PDF]

open access: yesCancers (Basel)
Horn PRCB   +16 more
europepmc   +1 more source

BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy

open access: yesCancer Science, EarlyView.
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao   +8 more
wiley   +1 more source

HVEM in acute lymphocytic leukemia facilitates tumour immune escape by inhibiting CD8<sup>+</sup> T cell function. [PDF]

open access: yesCell Oncol (Dordr)
Liu Y   +21 more
europepmc   +1 more source

Long Non‐Coding RNA, Like NEAT1 and MALAT1, in Asthma: Mechanisms and Therapeutic Potential

open access: yesClinical &Experimental Allergy, EarlyView.
Long non‐coding RNA, like NEAT1 and MALAT1, is emerging as a regulator of asthma‐related inflammation, airway remodelling, viral responses and cell death pathways, and are promising targets for future therapeutics. ABSTRACT Asthma affects millions worldwide. Long non‐coding RNA (lncRNA) are emerging as important factors in the pathophysiology of asthma
Ashlyn Poole   +4 more
wiley   +1 more source

Refining the boundary between myelodysplastic neoplasm and chronic myelomonocytic leukaemia under World Health Organization 2022 criteria using open‐source data

open access: yes
British Journal of Haematology, EarlyView.
Jiwon Yun   +5 more
wiley   +1 more source

Input Visualizations to Track Health Data by Older Adults with Multiple Chronic Conditions

open access: yesComputer Graphics Forum, EarlyView.
Abstract Older adults living with multiple chronic conditions (MCC) can considerably benefit from collecting and reflecting on their health data. Many older adults collect their health data using various approaches, such as digital tools or handwritten notebooks.
Shri Harini Ramesh   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy